CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES H. Quach; A. Nooka; O. Samoylova; C.P. Venner; T. Facon; A. Spencer; S.Z. Usmani; K. Weisel; M. Mateos; K. Kim; S. Grosicki; K. Suzuki; S. Delimpasi; M. Obreja; A. Zahlten-Kumeli;